These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 38273745

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].
    Muneta M, Ohmura Y, Takeda Y, Katsura Y, Shinke G, Kinoshita M, Aoyama S, Kihara Y, Katsuyama S, Ikeshima R, Hiraki M, Sugimura K, Masuzawa T, Hata T, Murata K.
    Gan To Kagaku Ryoho; 2023 Feb; 50(2):239-241. PubMed ID: 36807184
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
    Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ.
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):56-65. PubMed ID: 36328033
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N, Vogel A.
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
    [Abstract] [Full Text] [Related]

  • 9. Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma.
    Wheless M, Agarwal R, Goff L, Lockney N, Padmanabhan C, Heumann T.
    Curr Treat Options Oncol; 2024 Jan; 25(1):127-160. PubMed ID: 38177560
    [Abstract] [Full Text] [Related]

  • 10. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
    McNamara MG, Lopes A, Wasan H, Malka D, Goldstein D, Shannon J, Okusaka T, Knox JJ, Wagner AD, André T, Cunningham D, Moehler M, Jensen LH, Koeberle D, Bekaii-Saab T, Bridgewater J, Valle JW.
    J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
    Lee JK, Capanu M, O'Reilly EM, Ma J, Chou JF, Shia J, Katz SS, Gansukh B, Reidy-Lagunes D, Segal NH, Yu KH, Chung KY, Saltz LB, Abou-Alfa GK.
    Br J Cancer; 2013 Aug 20; 109(4):915-9. PubMed ID: 23900219
    [Abstract] [Full Text] [Related]

  • 13. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H, Türkmen I, Başsüllü N, Dirican A, Karadağ N, Kirimlioğlu V.
    Turk J Gastroenterol; 2009 Mar 20; 20(1):41-7. PubMed ID: 19330734
    [Abstract] [Full Text] [Related]

  • 14. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
    Zhang W, Luo C, Zhang ZY, Zhang BX, Chen XP.
    Front Immunol; 2022 Mar 20; 13():1079342. PubMed ID: 36700218
    [Abstract] [Full Text] [Related]

  • 15. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 16. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
    Lee KJ, Yi SW, Cha J, Seong J, Bang S, Song SY, Kim HM, Park SW.
    Cancer Chemother Pharmacol; 2016 Oct 15; 78(4):841-6. PubMed ID: 27586966
    [Abstract] [Full Text] [Related]

  • 17. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX.
    Best Pract Res Clin Gastroenterol; 2015 Apr 15; 29(2):355-61. PubMed ID: 25966434
    [Abstract] [Full Text] [Related]

  • 18. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG, Park JK, Kim HS, Kim K, Park JK, Lee KH, Lee KT, Lee JK.
    Scand J Gastroenterol; 2019 Jun 15; 54(6):740-745. PubMed ID: 31136212
    [Abstract] [Full Text] [Related]

  • 19. [A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma].
    Aoki Y, Suzuki T, Kato A, Shimizu H, Ohtsuka M, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Okamura D, Suzuki D, Sakai N, Kagawa S, Miyazaki M.
    Gan To Kagaku Ryoho; 2014 Nov 15; 41(12):1509-11. PubMed ID: 25731235
    [Abstract] [Full Text] [Related]

  • 20. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L.
    Front Biosci (Landmark Ed); 2022 Jun 08; 27(6):185. PubMed ID: 35748261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.